Showing results (351-360 of 513) with videos related to

Sort By:
Pageof 52
Asian Pacific Journal of Cancer Prevention : APJCP|March 27, 2019
Association of EGFR 1 Gene Alteration and their Association with Lung Adenocarcinoma PatientsMirza Masroor Ali Beg, Samer Riyadh Fahdil, Prasant Yadav, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|June 1, 2022
When "No-Smoking" is not enough: Hypoxia and nicotine acetylcholine receptor signaling may drive lung adenocarcinoma progression in never-smokersNamita Pandey, Jonita Chongtham, Soumyadip Pal, et al.
Tuberculosis (Edinburgh, Scotland)|March 22, 2018
Inhibiting HLA-G restores IFN-γ and TNF-α producing T cell in pleural TuberculosisAbhinav Saurabh, Sushmita Chakraborty, Prabin Kumar, et al.
Immunobiology|January 25, 2024
Hyperglycemia modulates M1/M2 macrophage polarization in chronic diabetic patients with pulmonary tuberculosis infectionSudhasini Panda, Alisha Arora, Kalpana Luthra, et al.
European Journal of Nutrition|June 27, 2002
Hyperhomocysteinemia, and low intakes of folic acid and vitamin B12 in urban North IndiaAnoop Misra, Naval K Vikram, R M Pandey, et al.
Transplantation Proceedings|October 25, 2021
Update on Coronavirus 2019 Vaccine Guidelines for Transplant RecipientsVivek Kute, Hari Shankar Meshram, Ashish Sharma, et al.
European Radiology|January 20, 2021
Artificial Intelligence-assisted chest X-ray assessment scheme for COVID-19Krithika Rangarajan, Sumanyu Muku, Amit Kumar Garg, et al.
Lung India : Official Organ of Indian Chest Society|May 3, 2024
A multicentre, double-blind, placebo-controlled randomized trial of Mycobacterium w in critically ill patients with COVID-19 (ARMY-2)Inderpaul S Sehgal, Ritesh Agarwal, Atul Jindal, et al.
Expert Review of Respiratory Medicine|September 26, 2022
A Delphi consensus statement for the management of post-COVID interstitial lung diseaseVijay Hadda, Tejas M Suri, Hariharan Iyer, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|September 6, 2021
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trialAnant Mohan, Pawan Tiwari, Tejas Menon Suri, et al.
Pageof 52